argenx SE is a Dutch‑Belgian biotechnology company focused on developing and commercializing antibody‑based therapies for immune‑mediated diseases. Founded in 2008, the company operates from the Netherlands and Belgium and is listed on Euronext Brussels and Nasdaq under the ticker ARGX.
Its lead product is efgartigimod, an FcRn antagonist marketed as VYVGART and VYVGART Hytrulo, approved in multiple regions for the treatment of generalized myasthenia gravis; the subcutaneous co‑formulation (Hytrulo) is also approved in the United States for chronic inflammatory demyelinating polyneuropathy (CIDP). argenx maintains a pipeline of antibody programs targeting autoimmune indications across neurology, hematology, and dermatology, progressing candidates through clinical development and working with external partners for manufacturing and commercialization.
